Analyst Scoreboard: 4 Ratings For ICU Medical
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for ICU Medical (NASDAQ:ICUI) over the past quarter, with a range of opinions from somewhat bullish to indifferent. The average 12-month price target has increased to $169.5, with a high of $190.00 and a low of $147.00. Recent analyst actions include upgrades and raised price targets, reflecting positive sentiment. ICU Medical, a leading infusion therapy company, has shown positive revenue growth and strong financial metrics, despite trailing industry peers in growth rate.
October 14, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ICU Medical has received mixed analyst ratings, with a recent increase in the average 12-month price target to $169.5. Analysts have shown positive sentiment with upgrades and raised price targets, indicating potential for stock appreciation.
The article highlights recent analyst ratings and price target increases for ICU Medical, indicating positive sentiment. The upgrades and raised targets suggest potential for stock appreciation, which is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100